Our Publications and Research
PLxGuard™ drug delivery platform has consistently demonstrated the potential to improve delivery and absorption of essential drugs currently on the market, and to reduce the risk of local gastrointestinal (GI) injury.
Papers
Influence of lipid excipients on platelet function and the pharmacodynamic effects of aspirin.
Schneider DJ, et al. J Cardiovasc Pharmacol. 2021;78(2):297-301.
Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation.
Angiolillo DJ, et al. J Thromb Thrombolysis. 2020;49(3):337-343.
Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study.
Angiolillo DJ, et al. J Thromb Thrombolysis. 2019;48(4):554-562.
Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus.
Bhatt DL, et al. J Am Coll Cardiol. 2017;69(6):603-612.
Unlocking aspirin’s chemopreventive activity: role of irreversibly inhibiting platelet cyclooxygenase-1.
Lichtenberger LM, et al. Cancer Prev Res. 2017;10(2):142-152.
Antitumor and antiangiogenic effects of aspirin-PC in ovarian cancer.
Huang Y, et al. Mol Cancer Ther. 2016;15(12):2894-2904.
Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial.
Cryer B, et al. Am J Gastroenterol. 2011;106(2):272-277.
Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity.
Lichtenberger LM, et al. Drugs Today (Barc). 2009;45(12):877-890.
Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients.
Lanza FL, et al. Aliment Pharmacol Ther. 2008;28(4):431-442.
Posters/Abstracts
Reduced gastric injury with a novel, liquid lipid-aspirin formulation: results from a pooled, patient level analysis of two randomized endoscopy studies in healthy volunteers.
Bhatt DL, et al. Virtual Poster at: ESC Virtual Congress; August 29-September 2, 2020.
Impact of sex on platelet inhibition by aspirin in obese patients with type 2 diabetes: a pooled, patient-level analysis of two randomized clinical trials.
Kimmelstiel C, et al. Abstract accepted at: EuroPCR; May 19-22, 2020. Conference cancelled due to COVID.
Improved pharmacologic profile of a novel, liquid aspirin formulation compared with enteric-coated aspirin: a pooled, patient level analysis of two randomized crossover studies.
Bhatt DL, et al. Poster presented at: American College of Cardiology’s 69th Annual Scientific Session & Expo; March 28-30, 2020; Chicago, IL.
Impact of weight on the antiplatelet effects of aspirin: results of a pooled analysis of two randomized crossover studies comparing a liquid aspirin formulation with enteric-coated aspirin.
Bhatt DL, et al. Poster presented at: American College of Cardiology’s 69th Annual Scientific Session & Expo; March 28-30, 2020; Chicago, IL.
Hospital budget impact of switching to an alternative aspirin formulation with improved GI safety for treatment of acute cardiovascular events.
Chingcuanco F, et al. Poster presented at: ISPOR; May 18-22, 2019; New Orleans, LA.
Limitations of enteric-coated aspirin underscore the need for a next generation, safer and effective aspirin formulation.
Chingcuanco F, et al. Poster presented at: ISPOR; May 18-22, 2019; New Orleans, LA.
Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation.
Angiolillo DJ, et al. Poster presented at: International Stroke Congress (ISC); February 18-21, 2020; Los Angeles, CA.
Pharmacokinetic and pharmacodynamic assessment of a lipid-based aspirin formulation: results of a prospective, randomized, crossover study.
Angiolillo DJ, et al. Poster presented at: European Society of Cardiology Congress (ESC); August 31-September 4, 2019; Paris, France.